CytomX Therapeutics
CytomX Therapeutics
CTMX
NASDAQ
1.18
USD
34.09%
About
CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated biologics designed to be localized to the tumor microenvironment. It is advancing potential first-in-class and best-in-class antibody-based therapeutics created using its PROBODY therapeutic technology platform.
Its pipeline comprises therapeutic candidates across multiple treatment modalities including antibody-drug conjugates (ADCs), T-cell engagers, and immune modulators such as cytokines. Its clinical-stage pipeline includes CX-904, CX-2051 and CX-801. CX-904 is a conditionally activated T-cell-engaging antibody targeting the epidermal growth factor receptor on tumor cells and the CD3 receptor on T cells and partnered with Amgen in a global co-development alliance.
CX-2051 is a conditionally activated ADC directed toward epithelial cell adhesion molecule (EpCAM) with potential applicability across multiple EpCAM-expressing epithelial cancers..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 401.6K |
| Three Month Average Volume | 25.4M |
| High Low | |
| Fifty-Two Week High | 5.85 USD |
| Fifty-Two Week Low | 1.04 USD |
| Fifty-Two Week High Date | 01 May 2024 |
| Fifty-Two Week Low Date | 30 Oct 2023 |
| Price and Volume | |
| Current Price | 1.18 USD |
| Beta | 1 |
| Relative Price Change | |
| Four Week Relative Price Change | -14.74% |
| Thirteen Week Relative Price Change | -35.15% |
| Twenty-Six Week Relative Price Change | -59.50% |
| Fifty-Two Week Relative Price Change | -37.22% |
| Year-to-Date Relative Price Change | -35.71% |
| Price Change | |
| One Day Price Change | 2.61% |
| Thirteen Week Price Change | -30.59% |
| Twenty-Six Week Price Change | -55.47% |
| Five Day Price Change | -2.48% |
| Fifty-Two Week Price Change | -21.33% |
| Year-to-Date Price Change | -23.87% |
| Month-to-Date Price Change | -14.49% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | -0.70489 USD |
| Book Value Per Share (Most Recent Quarter) | -0.39974 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | -0.72982 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | -0.42029 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | 0.09196 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 1.37131 USD |
| Revenue Per Share (Trailing Twelve Months) | 1.44906 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -0.00771 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | 0.13712 USD |
| Normalized (Last Fiscal Year) | -0.00771 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -0.00771 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | 0.13846 USD |
| Including Extraordinary Items (Last Fiscal Year) | -0.00771 USD |
| Including Extraordinary Items (Trailing Twelve Months) | 0.13712 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 2.59258 USD |
| Cash Per Share (Most Recent Quarter) | 1.7561 USD |
| Cash Flow Per Share (Last Fiscal Year) | 0.02176 USD |
| Cash Flow Per Share (Trailing Twelve Months) | 0.15733 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -1.0457 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -123 |
| Cash Flow Revenue (Trailing Twelve Months) | -72 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | 12.61% |
| Pretax Margin (Last Fiscal Year) | 3.28% |
| Pretax Margin (5 Year) | -103.37% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -6.41% |
| Operating Margin (Trailing Twelve Months) | 4.79% |
| Operating Margin (5 Year) | -109.68% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -0.56% |
| Net Profit Margin (Trailing Twelve Months) | 9.27% |
| Net Profit Margin (5 Year) | -100.38% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -99,999.99% |
| Tangible Book Value (5 Year) | -99,999.99% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | 1.58% |
| Revenue Growth (3 Year) | 11.21% |
| Revenue Change (Trailing Twelve Months) | 98.24% |
| Revenue Per Share Growth | -0.81% |
| Revenue Growth (5 Year) | 0.28% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -26.01% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | -371.11% |
| EPS Change (Trailing Twelve Months) | 114.74% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | -100,000 |
| Price to Tangible Book (Most Recent Quarter) | -100,000 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -137,182,000 |
| Net Debt (Last Fiscal Year) | -174,509,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 1 |
| Price to Sales (Trailing Twelve Months) | 1 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | 9 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | 9 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | 11 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | 9 |
| PE Including Extraordinary Items (Trailing Twelve Months) | 9 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | -100,000 |
| Price to Book (Most Recent Quarter) | -100,000 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | -100,000 |
| Long Term Debt to Equity (Most Recent Quarter) | -100,000 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | 0.00% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -107 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -4 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 1 |
| Current Ratio (Most Recent Quarter) | 1 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -56,875,000 |
| Free Cash Flow (Trailing Twelve Months) | -86,286,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | -100,000 |
| Total Debt to Equity (Most Recent Quarter) | -100,000 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -0.25% |
| Return on Assets (Trailing Twelve Months) | 6.02% |
| Return on Assets (5 Year) | -21.53% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -99,999.99% |
| Return on Equity (Trailing Twelve Months) | -99,999.99% |
| Return on Equity (5 Year) | -621.86% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -0.74% |
| Return on Investment (Trailing Twelve Months) | 26.34% |
| Return on Investment (5 Year) | -32.32% |